Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice 2-Year Results of the ISAR-ABSORB Registry

被引:22
|
作者
Wiebe, Jens [1 ]
Hoppmann, Petra [2 ]
Colleran, Roisin [1 ]
Kufner, Sebastian [1 ]
Valeskini, Michael [1 ]
Cassese, Salvatore [1 ]
Schneider, Simon [2 ]
Joner, Michael [1 ]
Schunkert, Heribert [1 ,3 ]
Laugwitz, Karl-Ludwig [2 ,3 ]
Kastrati, Adnan [1 ,3 ]
Byrne, Robert A. [1 ,3 ]
机构
[1] Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 1, Munich, Germany
[3] Partner Site Munich Heart Alliance, DZHK German Ctr Cardiovasc Res, Munich, Germany
关键词
bioresorbable stent(s); clinical outcomes; percutaneous coronary intervention; VASCULAR SCAFFOLD SYSTEM; CORONARY-ARTERY LESIONS; METALLIC STENTS; IMPLANTATION; INSIGHTS; IMPACT;
D O I
10.1016/j.jcin.2017.03.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The aim of this study was to report clinical outcomes in patients treated in routine practice 2 years after everolimus-eluting bioresorbable stent (BRS) implantation. BACKGROUND Long-term results in patients undergoing BRS implantation in routine clinical practice are sparse, and existing evidence from randomized trials considers mostly selected patients. METHODS The ISAR-ABSORB registry enrolled consecutive patients undergoing BRS implantation in routine clinical practice at 2 high-volume centers in Germany. Angiographic follow-up was scheduled after 6 to 8 months and clinical follow-up to 24 months. The primary endpoint was the composite of death, myocardial infarction, or target lesion revascularization, and secondary endpoints included individual components of the primary endpoint and definite stent thrombosis. Event rates were calculated using the Kaplan-Meier method. RESULTS A total of 419 patients were included. The mean age was 66.6 +/- 10.9 years, 31.5% had diabetes, and 39.0% presented with acute coronary syndrome. Forty-nine percent of lesions were considered complex (American College of Cardiology/American Heart Association type B2 or C), and 13.1% were bifurcation lesions. The mean reference vessel diameter was 2.89 +/- 0.46 mm. At 2 years, the primary endpoint had occurred in 21.6% of patients: death in 6.3%, myocardial infarction in 3.9%, target lesion revascularization in 16.0%, and definite stent thrombosis in 3.8%. CONCLUSIONS Long-term follow-up of patients treated with BRS in routine practice showed higher event rates than expected. Future studies are required to determine the impact of changes in implantation technique and to define the optimal duration of dual antiplatelet therapy in these patients. (C) 2017 by the American College of Cardiology Foundation.
引用
收藏
页码:1222 / 1229
页数:8
相关论文
共 50 条
  • [21] Diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: Clinical outcomes of a subgroup analysis from an all-comers absorb registry
    Camacho Freire, Santiago J.
    Roa-Garrido, Jessica
    Gomez Menchero, Antonio
    Cardenal, Rosa M.
    Leon Jimenez, Javier
    Gomez Fernandez, Prudencia
    Landero Garcia, Francisco J.
    Diaz Fernandez, Jose F.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (15) : B211 - B212
  • [22] 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds The ABSORB III Trial
    Kereiakes, Dean J.
    Ellis, Stephen G.
    Metzger, Christopher
    Caputo, Ronald P.
    Rizik, David G.
    Teirstein, Paul S.
    Litt, Marc R.
    Kini, Annapoorna
    Kabour, Ameer
    Marx, Steven O.
    Popma, Jeffrey J.
    McGreevy, Robert
    Zhang, Zhen
    Simonton, Charles
    Stone, Gregg W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (23) : 2852 - 2862
  • [23] Clinical outcomes following complete bioresorption of the Absorb everolimus-eluting bioresorbable scaffold: Four-year results from the ABSORB III trial
    Kereiakes, Dean
    Ellis, Stephen
    Stone, Gregg
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (13) : B27 - B27
  • [24] Absorb Bioresorbable Vascular Scaffolds vs. XIENCE Everolimus-Eluting Stents: Are Clinical Outcomes Different for Men and Women?
    Kereiakes, Dean
    Ellis, Stephen
    Gao, Runlin
    Kimura, Takeshi
    Onuma, Yoshinobu
    Piard-Ruster, Karine
    Zhang, Yunlong
    Koo, Kai
    Serruys, Patrick
    Stone, Gregg
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (18) : B168 - B168
  • [25] 1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds
    Muramatsu, Takashi
    Onuma, Yoshinobu
    van Geuns, Robert-Jan
    Chevalier, Bernard
    Patel, Tejas M.
    Seth, Ashok
    Diletti, Roberto
    Garcia-Garcia, Hector M.
    Dorange, Cecile C.
    Veldhof, Susan
    Cheong, Wai-Fung
    Ozaki, Yukio
    Whitbourn, Robert
    Bartorelli, Antonio
    Stone, Gregg W.
    Abizaid, Alexandre
    Serruys, Patrick W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (05) : 482 - 493
  • [27] Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials
    Campos, Carlos M.
    Caixeta, Adriano
    Franken, Marcelo
    Bartorelli, Antonio L.
    Whitbourn, Robert J.
    Wu, Chiung-Jen
    Kao, Hsien Li Paul
    Ali, Rosli Mohd
    Carrie, Didier
    De Bruyne, Bernard
    Stone, Gregg W.
    Serruys, Patrick W.
    Abizaid, Alexandre
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2018, 91 (03) : 387 - 395
  • [28] Impact of overlap on long-term clinical outcomes in patients undergoing everolimus-eluting bioresorbable vascular scaffolds implantation in routine clinical practice: insights from the European multicenter GHOST-EU registry
    Ortega-Paz, Luis
    Giacchi, Giuseppe
    Brugaletta, Salvatore
    Sabate, Manel
    Capodanno, Davide
    Gori, Tommaso
    Nef, Holger
    Latib, Azeem
    Mehilli, Julinda
    Lesiak, Maciej
    Caramanno, Giuseppe
    Naber, Christoph
    Di Mario, Carlo
    Colombo, Antonio
    Capranzano, Piera
    Wiebe, Jens
    Araszkiewicz, Aleksander
    Geraci, Salvatore
    Pyxaras, Stylianos A.
    Mattesini, Alessio
    Naganuma, Toru
    Munzel, Thomas
    Tamburino, Corrado
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (15) : B5 - B5
  • [29] Four-Year Clinical Outcomes From Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds Versus Everolimus-eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial
    Gao, Runlin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (13) : B128 - B128
  • [30] One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials
    Costa, Jose de Ribamar, Jr.
    Abizaid, Alexandre
    Bartorelli, Antonio L.
    Whitbourn, Robert
    Jepson, Nigel
    Perin, Marco
    Steinwender, Clemens
    Stuteville, Marrianne
    Ediebah, Divine
    Sudhir, Krishnankutty
    Serruys, Patrick W.
    EUROINTERVENTION, 2016, 12 (10) : 1255 - 1262